Compounds

Details Compounds Compounds

1999-08-20

2001-01-16

Slobodyansky, Elizabeth (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C435S069100, C435S069200, C435S252300, C435S320100, C435S366000, C536S023200, C536S023500

Reexamination Certificate

active

06174716

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to p101 polypeptides and polynucleotides, in particular p101 splice variant polypeptides and polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of diseases that involve leucocyte activation and infiltration including inflammatory diseases such as COPD, ARDS, arthritis, psoriasis and so on, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with p101 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate p101 activity or levels.


REFERENCES:
patent: 5856132 (1999-01-01), Stephens et al.
patent: 5869271 (1999-02-01), Stephens et al.
Stephens et al. The G&bgr;&ggr; Sensitivity of a P13K is Dependent upon a Tightly Associated Adaptor, p. 101, Cell, vol. 89, pp. 105-114 (1997).
GenBank Accession No. AI209071.
GenBank Accession No. AI209070.
GenBank Accession No. AI224130.
GenBank Accession No. AA355273.
GenBank Accession No. Y10742.
GenBank Accession No. AC002091.
GenBank Accession No. AC003695.

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2488183